title: Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study.
abstract: OBJECTIVE
  To determine whether cardiac iodine-123 metaiodobenzylguanidine ((123)I MIBG) imaging is useful in predicting the prognosis of patients with chronic heart failure.
  
  
  METHODS
  Cardiac (123)I MIBG imaging was done on entry to the study. The cardiac MIBG washout rate was calculated from anterior chest view images obtained 20 and 200 minutes after injection of the isotope. Study patients were divided into two groups with washout rates above and below 27% (the mean value + 2 SD obtained in 20 normal subjects), and were then followed up.
  
  
  METHODS
  Tertiary referral centre.
  
  
  METHODS
  79 patients with chronic heart failure in whom the left ventricular ejection fraction was less than 40%.
  
  
  RESULTS
  There were 37 patients in group 1 (washout rate of >/= 27%) and 42 in group 2 (< 27%). During a follow up period of between 1 and 52 months, eight patients died suddenly and five died of worsening heart failure in group 1, while none died in group 2; 13 patients in group 1 and four in group 2 were admitted to hospital for progressive heart failure. Kaplan-Meier analysis showed that group 1 had a significantly higher mortality and morbidity (p = 0.001 and p < 0.001, respectively) than group 2.
  
  
  CONCLUSIONS
  Cardiac (123)I MIBG washout rate seems to be a good predictor of prognosis in patients with chronic heart failure.
authors.affiliation: Division of Cardiology, Osaka Prefectural General Hospital, 3-1-56 Mandai-Higashi Sumiyoshi-ku, Osaka 558-8558, Japan. hogita@medone.med.osaka-u.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Ogita
authors.forename: T
authors.initials: T
authors.lastname: Shimonagata
authors.forename: M
authors.initials: M
authors.lastname: Fukunami
authors.forename: K
authors.initials: K
authors.lastname: Kumagai
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: Y
authors.initials: Y
authors.lastname: Asano
authors.forename: A
authors.initials: A
authors.lastname: Hirata
authors.forename: M
authors.initials: M
authors.lastname: Asai
authors.forename: H
authors.initials: H
authors.lastname: Kusuoka
authors.forename: M
authors.initials: M
authors.lastname: Hori
authors.forename: N
authors.initials: N
authors.lastname: Hoki
mesh_terms: D019797:3-Iodobenzylguanidine; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood / Q000000981:diagnostic imaging* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011379:Prognosis; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D016019:Survival Analysis; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology
chemical_list: D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; D009638:Norepinephrine